Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups

Brandon A Mahal; Ayal A Aizer; David R Ziehr; Andrew S Hyatt; Jesse Sammon; Marianne Schmid; Toni K Choueiri; Jim C Hu; Christopher J Sweeney; Clair J Beard; Anthony V D'Amico; Neil E Martin; Simon P Kim; Quoc-Dien Trinh; Paul L Nguyen

doi:10.1016/j.urology.2014.05.009

Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups

Standard

Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups. / Mahal, Brandon A; Aizer, Ayal A; Ziehr, David R; Hyatt, Andrew S; Sammon, Jesse; Schmid, Marianne; Choueiri, Toni K; Hu, Jim C; Sweeney, Christopher J; Beard, Clair J; D'Amico, Anthony V; Martin, Neil E; Kim, Simon P; Trinh, Quoc-Dien; Nguyen, Paul L.

In: UROLOGY, Vol. 84, No. 2, 01.08.2014, p. 386-392.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Mahal, BA, Aizer, AA, Ziehr, DR, Hyatt, AS, Sammon, J, Schmid, M, Choueiri, TK, Hu, JC, Sweeney, CJ, Beard, CJ, D'Amico, AV, Martin, NE, Kim, SP, Trinh, Q-D & Nguyen, PL 2014, 'Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups', UROLOGY, vol. 84, no. 2, pp. 386-392. https://doi.org/10.1016/j.urology.2014.05.009

APA

Mahal, B. A., Aizer, A. A., Ziehr, D. R., Hyatt, A. S., Sammon, J., Schmid, M., Choueiri, T. K., Hu, J. C., Sweeney, C. J., Beard, C. J., D'Amico, A. V., Martin, N. E., Kim, S. P., Trinh, Q-D., & Nguyen, P. L. (2014). Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups. UROLOGY, 84(2), 386-392. https://doi.org/10.1016/j.urology.2014.05.009

Vancouver

Mahal BA, Aizer AA, Ziehr DR, Hyatt AS, Sammon J, Schmid M et al. Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups. UROLOGY. 2014 Aug 1;84(2):386-392. https://doi.org/10.1016/j.urology.2014.05.009

Bibtex

@article{6118f8189f91475f925eb0a0d4647900,

title = "Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups",

abstract = "OBJECTIVE: To determine whether African Americans (AAs) with intermediate- to high-risk prostate cancer (PCa) receive similar treatment as white patients and whether any observed disparities are narrowing with time.METHODS: We used Surveillance, Epidemiology, and End Results to identify 128,189 men with localized intermediate- to high-risk PCa (prostate-specific antigen ≥10 ng/mL, Gleason score ≥7, or T stage ≥T2b) diagnosed from 2004 to 2010. We used multivariate logistic regression analyses to determine the impact of race on the receipt of definitive treatment.RESULTS: AA men were significantly less likely to receive curative-intent treatment than white men (adjusted odds ratio [AOR], 0.82; 95% confidence interval [CI], 0.79-0.86; P <.001). There was no evidence of this disparity narrowing over time (Pinteraction 2010 vs 2004 = .490). Disparities in the receipt of treatment between AA and white men were significantly larger in high-risk (AOR, 0.60; 95% CI, 0.56-0.64; P <.001) than in intermediate-risk disease (AOR, 0.92; 95% CI, 0.88-0.97; P = .04; Pinteraction <.001). After adjusting for treatment, demographics, and prognostic factors, AA men had a higher risk of prostate cancer-specific mortality (adjusted hazard ratio, 1.12; 95% CI, 1.01-1.25; P = .03).CONCLUSION: AA men with intermediate- to high-risk PCa are less likely to be treated with curative intent than white men. This disparity is worse in high-risk disease and is not improving over time. Factors underlying this treatment disparity should be urgently studied as it is a potentially correctable contributor to excess PCa mortality among AA patients.",

keywords = "African Americans, Aged, European Continental Ancestry Group, Healthcare Disparities, Humans, Male, Middle Aged, Prostatic Neoplasms, Risk Factors, SEER Program, United States",

author = "Mahal, {Brandon A} and Aizer, {Ayal A} and Ziehr, {David R} and Hyatt, {Andrew S} and Jesse Sammon and Marianne Schmid and Choueiri, {Toni K} and Hu, {Jim C} and Sweeney, {Christopher J} and Beard, {Clair J} and D'Amico, {Anthony V} and Martin, {Neil E} and Kim, {Simon P} and Quoc-Dien Trinh and Nguyen, {Paul L}",

year = "2014",

month = aug,

day = "1",

doi = "10.1016/j.urology.2014.05.009",

language = "English",

volume = "84",

pages = "386--392",

journal = "UROLOGY",

issn = "0090-4295",

publisher = "Elsevier Inc.",

number = "2",

}

RIS

TY - JOUR

T1 - Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups

AU - Mahal, Brandon A

AU - Aizer, Ayal A

AU - Ziehr, David R

AU - Hyatt, Andrew S

AU - Sammon, Jesse

AU - Schmid, Marianne

AU - Choueiri, Toni K

AU - Hu, Jim C

AU - Sweeney, Christopher J

AU - Beard, Clair J

AU - D'Amico, Anthony V

AU - Martin, Neil E

AU - Kim, Simon P

AU - Trinh, Quoc-Dien

AU - Nguyen, Paul L

PY - 2014/8/1

Y1 - 2014/8/1

N2 - OBJECTIVE: To determine whether African Americans (AAs) with intermediate- to high-risk prostate cancer (PCa) receive similar treatment as white patients and whether any observed disparities are narrowing with time.METHODS: We used Surveillance, Epidemiology, and End Results to identify 128,189 men with localized intermediate- to high-risk PCa (prostate-specific antigen ≥10 ng/mL, Gleason score ≥7, or T stage ≥T2b) diagnosed from 2004 to 2010. We used multivariate logistic regression analyses to determine the impact of race on the receipt of definitive treatment.RESULTS: AA men were significantly less likely to receive curative-intent treatment than white men (adjusted odds ratio [AOR], 0.82; 95% confidence interval [CI], 0.79-0.86; P <.001). There was no evidence of this disparity narrowing over time (Pinteraction 2010 vs 2004 = .490). Disparities in the receipt of treatment between AA and white men were significantly larger in high-risk (AOR, 0.60; 95% CI, 0.56-0.64; P <.001) than in intermediate-risk disease (AOR, 0.92; 95% CI, 0.88-0.97; P = .04; Pinteraction <.001). After adjusting for treatment, demographics, and prognostic factors, AA men had a higher risk of prostate cancer-specific mortality (adjusted hazard ratio, 1.12; 95% CI, 1.01-1.25; P = .03).CONCLUSION: AA men with intermediate- to high-risk PCa are less likely to be treated with curative intent than white men. This disparity is worse in high-risk disease and is not improving over time. Factors underlying this treatment disparity should be urgently studied as it is a potentially correctable contributor to excess PCa mortality among AA patients.

AB - OBJECTIVE: To determine whether African Americans (AAs) with intermediate- to high-risk prostate cancer (PCa) receive similar treatment as white patients and whether any observed disparities are narrowing with time.METHODS: We used Surveillance, Epidemiology, and End Results to identify 128,189 men with localized intermediate- to high-risk PCa (prostate-specific antigen ≥10 ng/mL, Gleason score ≥7, or T stage ≥T2b) diagnosed from 2004 to 2010. We used multivariate logistic regression analyses to determine the impact of race on the receipt of definitive treatment.RESULTS: AA men were significantly less likely to receive curative-intent treatment than white men (adjusted odds ratio [AOR], 0.82; 95% confidence interval [CI], 0.79-0.86; P <.001). There was no evidence of this disparity narrowing over time (Pinteraction 2010 vs 2004 = .490). Disparities in the receipt of treatment between AA and white men were significantly larger in high-risk (AOR, 0.60; 95% CI, 0.56-0.64; P <.001) than in intermediate-risk disease (AOR, 0.92; 95% CI, 0.88-0.97; P = .04; Pinteraction <.001). After adjusting for treatment, demographics, and prognostic factors, AA men had a higher risk of prostate cancer-specific mortality (adjusted hazard ratio, 1.12; 95% CI, 1.01-1.25; P = .03).CONCLUSION: AA men with intermediate- to high-risk PCa are less likely to be treated with curative intent than white men. This disparity is worse in high-risk disease and is not improving over time. Factors underlying this treatment disparity should be urgently studied as it is a potentially correctable contributor to excess PCa mortality among AA patients.

KW - African Americans

KW - Aged

KW - European Continental Ancestry Group

KW - Healthcare Disparities

KW - Humans

KW - Male

KW - Middle Aged

KW - Prostatic Neoplasms

KW - Risk Factors

KW - SEER Program

KW - United States

U2 - 10.1016/j.urology.2014.05.009

DO - 10.1016/j.urology.2014.05.009

M3 - SCORING: Journal article

C2 - 24975710

VL - 84

SP - 386

EP - 392

JO - UROLOGY

JF - UROLOGY

SN - 0090-4295

IS - 2

ER -